Lakefront Biotherapeutics American Depositary Shares
LKFT
92 hedge funds and large institutions have $993M invested in Lakefront Biotherapeutics American Depositary Shares in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 27 reducing their positions, and 13 closing their positions.
127% more call options, than puts
Call options by funds: $74M | Put options by funds: $32.6M
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
33% more capital invested
Capital invested by funds: $746M → $993M (+$247M)
15% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 27
8% more funds holding
Funds holding: 85 → 92 (+7)
0.56% more ownership
Funds ownership: 14.93% → 15.48% (+0.56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$30.2M |
| 2 |
Alkeon Capital Management
New York
|
+$17.6M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$13.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$11.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$7.06M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$5.77M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$5.17M |
| 5 |
Jane Street
New York
|
-$5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PC
101
PA Capital
Richmond,
Virginia
| – | -$314K | -3,425 | Closed |
|
|
TI
102
Trexquant Investment
Stamford,
Connecticut
| – | -$254K | -2,774 | Closed |
|
|
CA
103
Claro Advisors
Boston,
Massachusetts
| – | -$43K | -382 | Closed |
|
|
MOS
104
MGO One Seven
Beachwood,
Ohio
| – | -$27K | -302 | Closed |
|
105
Simplex Trading
Chicago,
Illinois
| – | -$1.81K | -18 | Closed |
|
LKFT Hedge Fund Activity: Q1 2019 in Review
92 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2019, worth a combined $993M — up 33% from $746M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LKFT positions and 13 closed out — a net gain of 8 holders — while 31 added to existing stakes and 27 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $30.2M. The largest seller was Deerfield Management, cutting an estimated $11.2M.
- 92 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2019, up from 85 in Q4 2018.
- Funds reported $993M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2019, up 33% quarter-over-quarter.
- 21 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2019 and 13 closed out, a net change of +8 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2019 was Cormorant Asset Management, an estimated $30.2M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2019 was Deerfield Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2019.